- Home
- AU vs TFX Comparison
AU vs TFX Comparison
Compare AU & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AU
- TFX
- Stock Information
- Founded
- AU 1944
- TFX 1943
- Country
- AU United States
- TFX United States
- Employees
- AU N/A
- TFX N/A
- Industry
- AU Precious Metals
- TFX Medical/Dental Instruments
- Sector
- AU Basic Materials
- TFX Health Care
- Exchange
- AU Nasdaq
- TFX Nasdaq
- Market Cap
- AU 30.2B
- TFX 5.8B
- IPO Year
- AU 1972
- TFX N/A
- Fundamental
- Price
- AU $64.61
- TFX $125.80
- Analyst Decision
- AU Buy
- TFX Hold
- Analyst Count
- AU 5
- TFX 9
- Target Price
- AU $47.30
- TFX $141.57
- AVG Volume (30 Days)
- AU 3.3M
- TFX 599.7K
- Earning Date
- AU 11-06-2025
- TFX 10-30-2025
- Dividend Yield
- AU 1.43%
- TFX 1.08%
- EPS Growth
- AU 1303.37
- TFX N/A
- EPS
- AU 3.81
- TFX 4.18
- Revenue
- AU $7,649,000,000.00
- TFX $3,041,342,000.00
- Revenue This Year
- AU $62.30
- TFX $10.39
- Revenue Next Year
- AU N/A
- TFX $10.67
- P/E Ratio
- AU $16.95
- TFX $30.20
- Revenue Growth
- AU 54.59
- TFX 1.11
- 52 Week Low
- AU $22.45
- TFX $108.90
- 52 Week High
- AU $67.67
- TFX $249.91
- Technical
- Relative Strength Index (RSI)
- AU 67.01
- TFX 49.72
- Support Level
- AU $56.68
- TFX $125.05
- Resistance Level
- AU $67.67
- TFX $129.29
- Average True Range (ATR)
- AU 1.95
- TFX 2.97
- MACD
- AU 0.29
- TFX -0.80
- Stochastic Oscillator
- AU 75.70
- TFX 23.52
About AU AngloGold Ashanti PLC
Anglogold Ashanti PLC is one of the gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from the Africa region which includes its operations of the Kibali, Iduapriem, Obuasi, Siguiri, and Geita mines.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.